Derzeitiger stellenwert intravenöser valproinsäure in der therapie des generalisierten tonisch-klonischen status epilepticus: Ergebnisse einer expertenkonferenz, Zürich, 17. und 18. Dezember 2004

Günter Krämer; A. Bergmann; P. A. Despland; S. König; G. Kurlemann; C. Kurth; W. Löscher; G. Luef; H. Meierkord; S. Noachtar; B. Pohlmann-Eden; F. Rosenow; S. Rüegg; U. Runge; D. Schmidt; B. Schmitt; A. Siegel; H. Stefan; S. Stodieck; E. Taubøll; E. Trinka; M. Überall

doi:10.1055/s-2005-866872

Derzeitiger stellenwert intravenöser valproinsäure in der therapie des generalisierten tonisch-klonischen status epilepticus: Ergebnisse einer expertenkonferenz, Zürich, 17. und 18. Dezember 2004

Günter Krämer, A. Bergmann, P. A. Despland, S. König, G. Kurlemann, C. Kurth, W. Löscher, G. Luef, H. Meierkord, S. Noachtar, B. Pohlmann-Eden, F. Rosenow, S. Rüegg, U. Runge, D. Schmidt, B. Schmitt, A. Siegel, H. Stefan, S. Stodieck, E. TaubøllE. Trinka, M. Überall

Résultat de recherche: Review article › examen par les pairs

12 Citations (Scopus)

Résumé

In spite of lacking approval intravenous valproic acid (VPA) is used for therapy of status epilepticus (SE) including status epilepticus of generalized tonic-clonic seizures (SEGTCS). Evidence class I and II data from randomised and blinded studies are not available. An expert panel including basic scientists and neuropediatricians as well as neurologists evaluated and summarized the currently available data from the literature and the clinical experience of the participating authors regarding the use of intravenous VPA in SE. In the german speaking countries intravenous VPA is not yet approved for therapy of SE. It is used "off-label" based on evidence from class III and IV data following unsuccessful pretreatment with benzodiazepines, phenytoin, or phenobarbital. Recommendations regarding dosage and monitoring are given. A prospective registre of the use of intravenous VPA in SEGTCS is suggested to get more reliable data.

Titre traduit de la contribution	Current place of intravenous valproic acid in the treatment of generalized tonic-clonic status epilepticus: Results of a panel of experts, Zurich, December 17-18, 2004
Langue d'origine	German
Pages (de-à)	263-274
Nombre de pages	12
Journal	Aktuelle Neurologie
Volume	32
Numéro de publication	5
DOI	https://doi.org/10.1055/s-2005-866872
Statut de publication	Published - juin 2005
Publié à l'externe	Oui

ASJC Scopus Subject Areas

Clinical Neurology

Accès au document

10.1055/s-2005-866872

Autres fichiers et liens

Empreinte numérique

Plonger dans les sujets de recherche 'Derzeitiger stellenwert intravenöser valproinsäure in der therapie des generalisierten tonisch-klonischen status epilepticus: Ergebnisse einer expertenkonferenz, Zürich, 17. und 18. Dezember 2004'. Ensemble, ils forment une empreinte numérique unique.

Citer

Krämer, G., Bergmann, A., Despland, P. A., König, S., Kurlemann, G., Kurth, C., Löscher, W., Luef, G., Meierkord, H., Noachtar, S., Pohlmann-Eden, B., Rosenow, F., Rüegg, S., Runge, U., Schmidt, D., Schmitt, B., Siegel, A., Stefan, H., Stodieck, S., ... Überall, M. (2005). Derzeitiger stellenwert intravenöser valproinsäure in der therapie des generalisierten tonisch-klonischen status epilepticus: Ergebnisse einer expertenkonferenz, Zürich, 17. und 18. Dezember 2004. Aktuelle Neurologie, 32(5), 263-274. https://doi.org/10.1055/s-2005-866872

Derzeitiger stellenwert intravenöser valproinsäure in der therapie des generalisierten tonisch-klonischen status epilepticus: Ergebnisse einer expertenkonferenz, Zürich, 17. und 18. Dezember 2004. / Krämer, Günter; Bergmann, A.; Despland, P. A. et al.
Dans: Aktuelle Neurologie, Vol. 32, N° 5, 06.2005, p. 263-274.

Résultat de recherche: Review article › examen par les pairs

Krämer, G, Bergmann, A, Despland, PA, König, S, Kurlemann, G, Kurth, C, Löscher, W, Luef, G, Meierkord, H, Noachtar, S, Pohlmann-Eden, B, Rosenow, F, Rüegg, S, Runge, U, Schmidt, D, Schmitt, B, Siegel, A, Stefan, H, Stodieck, S, Taubøll, E, Trinka, E & Überall, M 2005, 'Derzeitiger stellenwert intravenöser valproinsäure in der therapie des generalisierten tonisch-klonischen status epilepticus: Ergebnisse einer expertenkonferenz, Zürich, 17. und 18. Dezember 2004', Aktuelle Neurologie, vol. 32, n° 5, pp. 263-274. https://doi.org/10.1055/s-2005-866872

@article{6bfa9ab032974e4ca5a9fc95228d4395,

title = "Derzeitiger stellenwert intraven{\"o}ser valproins{\"a}ure in der therapie des generalisierten tonisch-klonischen status epilepticus: Ergebnisse einer expertenkonferenz, Z{\"u}rich, 17. und 18. Dezember 2004",

abstract = "In spite of lacking approval intravenous valproic acid (VPA) is used for therapy of status epilepticus (SE) including status epilepticus of generalized tonic-clonic seizures (SEGTCS). Evidence class I and II data from randomised and blinded studies are not available. An expert panel including basic scientists and neuropediatricians as well as neurologists evaluated and summarized the currently available data from the literature and the clinical experience of the participating authors regarding the use of intravenous VPA in SE. In the german speaking countries intravenous VPA is not yet approved for therapy of SE. It is used {"}off-label{"} based on evidence from class III and IV data following unsuccessful pretreatment with benzodiazepines, phenytoin, or phenobarbital. Recommendations regarding dosage and monitoring are given. A prospective registre of the use of intravenous VPA in SEGTCS is suggested to get more reliable data.",

author = "G{\"u}nter Kr{\"a}mer and A. Bergmann and Despland, {P. A.} and S. K{\"o}nig and G. Kurlemann and C. Kurth and W. L{\"o}scher and G. Luef and H. Meierkord and S. Noachtar and B. Pohlmann-Eden and F. Rosenow and S. R{\"u}egg and U. Runge and D. Schmidt and B. Schmitt and A. Siegel and H. Stefan and S. Stodieck and E. Taub{\o}ll and E. Trinka and M. {\"U}berall",

year = "2005",

month = jun,

doi = "10.1055/s-2005-866872",

language = "Allemand",

volume = "32",

pages = "263--274",

journal = "Aktuelle Neurologie",

issn = "0302-4350",

number = "5",

}

TY - JOUR

T1 - Derzeitiger stellenwert intravenöser valproinsäure in der therapie des generalisierten tonisch-klonischen status epilepticus

T2 - Ergebnisse einer expertenkonferenz, Zürich, 17. und 18. Dezember 2004

AU - Krämer, Günter

AU - Bergmann, A.

AU - Despland, P. A.

AU - König, S.

AU - Kurlemann, G.

AU - Kurth, C.

AU - Löscher, W.

AU - Luef, G.

AU - Meierkord, H.

AU - Noachtar, S.

AU - Pohlmann-Eden, B.

AU - Rosenow, F.

AU - Rüegg, S.

AU - Runge, U.

AU - Schmidt, D.

AU - Schmitt, B.

AU - Siegel, A.

AU - Stefan, H.

AU - Stodieck, S.

AU - Taubøll, E.

AU - Trinka, E.

AU - Überall, M.

PY - 2005/6

Y1 - 2005/6

N2 - In spite of lacking approval intravenous valproic acid (VPA) is used for therapy of status epilepticus (SE) including status epilepticus of generalized tonic-clonic seizures (SEGTCS). Evidence class I and II data from randomised and blinded studies are not available. An expert panel including basic scientists and neuropediatricians as well as neurologists evaluated and summarized the currently available data from the literature and the clinical experience of the participating authors regarding the use of intravenous VPA in SE. In the german speaking countries intravenous VPA is not yet approved for therapy of SE. It is used "off-label" based on evidence from class III and IV data following unsuccessful pretreatment with benzodiazepines, phenytoin, or phenobarbital. Recommendations regarding dosage and monitoring are given. A prospective registre of the use of intravenous VPA in SEGTCS is suggested to get more reliable data.

AB - In spite of lacking approval intravenous valproic acid (VPA) is used for therapy of status epilepticus (SE) including status epilepticus of generalized tonic-clonic seizures (SEGTCS). Evidence class I and II data from randomised and blinded studies are not available. An expert panel including basic scientists and neuropediatricians as well as neurologists evaluated and summarized the currently available data from the literature and the clinical experience of the participating authors regarding the use of intravenous VPA in SE. In the german speaking countries intravenous VPA is not yet approved for therapy of SE. It is used "off-label" based on evidence from class III and IV data following unsuccessful pretreatment with benzodiazepines, phenytoin, or phenobarbital. Recommendations regarding dosage and monitoring are given. A prospective registre of the use of intravenous VPA in SEGTCS is suggested to get more reliable data.

UR - http://www.scopus.com/inward/record.url?scp=21344457218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344457218&partnerID=8YFLogxK

U2 - 10.1055/s-2005-866872

DO - 10.1055/s-2005-866872

M3 - Artículo de revisión

AN - SCOPUS:21344457218

SN - 0302-4350

VL - 32

SP - 263

EP - 274

JO - Aktuelle Neurologie

JF - Aktuelle Neurologie

IS - 5

ER -